Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium channel subfamily K member 5 (KCNK5)
- Target
- KCNK5
- Molecular classification
- Ion channel, Two pore-domain potassium channel (K2P channel), Tandem pore domain potassium channel
01
Overview
Potassium channel subfamily K member 5 (KCNK5), also known as TASK2 or K2P5.1, is a member of the two-pore domain potassium channel (K2P) family characterized by two pore-forming domains per subunit and dimeric assembly[1][2]. It is highly sensitive to extracellular pH and mainly expressed in the kidney's cortical distal tubules and collecting ducts, where it plays a crucial role in renal potassium transport and maintaining membrane potential. In addition to its renal functions, KCNK5 has been implicated in pH sensing, regulation of cell volume, spermatozoa function, and immune cell proliferation[1][3][4][5]. Disruption of KCNK5 function may contribute to renal tubular disorders, abnormalities in potassium handling, and potential immune dysfunction.
- Other names
- TASK2K2P5.1TWIK-related acid-sensitive K(+) channel 2Acid-sensitive potassium channel protein TASK-2potassium channel two-pore domain subfamily K member 5potassium channel subfamily K member 5TASK-2
02
Mechanism of action
Most modulators act by altering channel gating or its proton-sensing ability, thereby affecting potassium flow and cell membrane potential
03
Biological functions
Regulation of membrane potentialRegulation of cell volumeRenal potassium transportpH sensing/proton sensitivityRegulatory volume decrease in spermatozoaNK-cell proliferation and cytolytic function
04
Disease associations
Renal disorders (particularly related to tubular function and potassium handling)May play roles in immune system function (NK-cell proliferation)Other roles in diseases listed for potassium channels (potential but less directly referenced to KCNK5): hypertension, acid-base balance disorders, possibly some cancers
05
Safety considerations
Modulation of KCNK5 activity may impact renal potassium handling and systemic electrolyte balancePotential off-target effects on membrane excitability in tissues outside the kidney
06
Interacting drugs
There are no highly specific, clinically used drugs known to directly target KCNK5; general potassium channel modulators and blockers may affect it, but specific ligands are not well established
07
Biomarkers
No established biomarkers for patient selection or efficacy directly associated with KCNK5
Beyond the preview
Go deeper on Potassium channel subfamily K member 5 (KCNK5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Potassium channel subfamily K member 5 (KCNK5).